The investment in Indian clinical technology expertise in Hyderabad comes amid the clinical trials sector's move towards decentralised trials
The investment will establish additional capacity across the entire global value chain from manufacturing of active pharmaceutical ingredients (API) to assembly and packaging, with the vast majority being invested in API capacity
This is the fourth facility from the company to receive this registration
Serum has a capacity of 250-275 million whereas Bharat Biotech has a capacity of 50-60 million
The partnership will help advance GreenLight's messenger RNA Covid-19 vaccine candidate
The process is completed with the help of a balloon at a low temperature so that other cells are undamaged and the patient can return home the next day
Its unique technology, ChetoSensar gives new promise to ADCs by alleviating solubility challenges
Support from DFC will help produce one billion vaccine doses by the end of 2022
This new lyophilizer is equipped with systems to best protect high value Active Pharmaceutical Ingredients (APIs) and doubles the lyophilization capacity at the site
An amount of Rs. 70.9 crore has been earmarked for funding capital expenditure for the proposed expansion
Subscribe To Our Newsletter & Stay Updated
